Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "daiichi sankyo"

Exelixis' collaborator Daiichi Sankyo begins phase 3 trial to ...

Exelixis, Inc., a biopharmaceutical company, announced that its partner Daiichi Sankyo Company, Limited has initiated a phase 3 pivotal trial to evaluate CS-3150 (esaxerenone (r-INN)), an oral, non-steroidal, selective mineralocorticoid receptor ... PharmaBiz, 10 hours ago
[x]  

52 images for daiichi sankyo

PharmaVOICE, 4 weeks ago
Pharma Letter, 4 weeks ago
Freshnews.com, 1 month ago
Freshnews.com, 1 month ago
Minyanville, 1 month ago
Nasdaq, 2 months ago
Zacks.com, 2 months ago
Nasdaq, 2 months ago
Finchannel.com, 2 months ago
Business Insider, 3 months ago

Daiichi Sankyo seeks Japanese approval for additional indication of denosumab to treat RA

Daiichi Sankyo Company, Limited announced that it has applied for additional indication of denosumab (product name: Pralia subcutaneous injection 60mg syringe) for rheumatoid arthritis-related treatment. Denosumab is the first fully human ...
 PharmaBiz3 days ago Daiichi Sankyo Announces Application in Japan for Additional Indication for Anti-RANKL Antibody, Denosumab  FirstWord Pharma4 days ago

Daiichi Sankyo, UCB introduce antiepileptic drug, Vimpat tablets

Daiichi Sankyo Company, Limited and UCB Japan Co., Ltd have announced that they have launched Vimpat tablets 50 mg and 100 mg (generic name: lacosamide; date of approval: July 4, 2016; date of listing in the NHI reimbursement price list in Japan: ...
 PharmaBiz3 weeks ago DAIICHI SANKYO : Antiepileptic Drug Vimpat® Tablets 50 mg and 100 mg have been launched.  4 Traders3 weeks ago
Pharma Letter

Daiichi Sankyo phase 3b ENSURE-AF study of once-daily Lixiana in patients with AF undergoing cardioversion meets primary endpoints

Daiichi Sankyo Company, Limited announced results from the global phase 3b ENSURE-AF study of 2,199 patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion (low-energy shocks to trigger normal heart rhythm). The ...
 PharmaBiz3 weeks ago Phase IIIb data backs Daiichi Sankyo's Lixiana in atrial fibrillation patients undergoing cardioversion  Pharma Letter4 weeks ago Daiichi Sankyo, Inc. Adds to Its Dynamic Team, Welcoming Leigh Ann Errico as the New Vice President of Human Resources for the U.S. Commercial Group  PharmaVOICE4 weeks ago Daiichi Sankyo Adds Leigh Ann Errico as VP of Human Resources  Citybizlist1 month ago
[x]  

WORLD HEART FEDERATION, DAIICHI SANKYO AND LILLY PARTNER TO IMPROVE CARDIOVASCULAR HEALTH

 World Heart Federation1 week ago DAIICHI SANKYO : Reports from Daiichi Sankyo Add New Data to Findings in Thrombosis (Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in...  4 Traders1 week ago DAIICHI SANKYO : New Findings on Carboxylic Ester Hydrolases from Daiichi Sankyo Summarized (Identification of a novel boronic acid as a potent, selective, and orally...  4 Traders2 weeks ago ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyo's Once-​Daily LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion  Ariva.de4 weeks ago
[x]  

Daiichi and UCB file for new indication for lacosamide in Japan

Daiichi Sankyo and UCB have filed an application for partial amendment of approval to
 Pharma Letter1 month ago Daiichi, UCB file application for partial amendment of approval to use lacosamide for epilepsy patients  PharmaBiz1 month ago DAIICHI SANKYO : Antiepileptic lacosamide filed for partial amendment of approval to add a new indication in Japan  4 Traders1 month ago
Freshnews.com

Daiichi moves TMFs, other R&D documents onto Veeva cloud platform

Daiichi Sankyo has struck a deal to use Veeva Systems ($VEEV) cloud platform to store its R&D files. The agreement sees Daiichi use Veeva Vault to manage electronic trial master files (eTMFs), quality compliance documents and the submission assembly ...
 FierceBiotech1 month ago Daiichi Sankyo Selects Vault To Streamline Submissions, eTMF, And Quality Management  BioSpace1 month ago Daiichi Sankyo Selects Veeva Vault to Streamline Submissions, eTMF, and Quality Management  SPi World News1 month ago Daiichi Sankyo chooses Veeva Vault to streamline submissions, eTMF, and quality management  Pharmaceutical Business Review1 month ago
[x]  

Daiichi Sankyo To Present At Late-Breaking Clinical Data For Novel HER2-Targeting Antibody Drug Conjugate In T-DM1 Pre-Treated Breast Cancer

TOKYO , PARSIPPANY, N.J. , and MUNICH , Sept. 27, 2016 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that safety and preliminary efficacy phase 1 data evaluating DS-8201a, a novel HER2-targeting antibody ...
 BioSpace1 hour ago Daiichi Sankyo to Present at ESMO 2016 Late-Breaking Clinical Data for Novel HER2-Targeting Antibody Drug Conjugate in T-DM1 Pre-Treated Breast Cancer  International Business Times5 hours ago
[x]  
Freshnews.com

Global DNA Gyrase Subunit B (EC 5.99.1.3) Pipeline Review 2016 Featuring Abgentis, AstraZeneca, Daiichi Sankyo Company & Merck & Co. - Research and Markets

has announced the addition of the "DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H1 2016" report to
 BioSpace3 weeks ago Global Alzheimers Disease Therapeutics and Diagnostics Market Driven by Rising Aging Population  Digital Journal1 day ago Hypercholesterolemia Drugs Market Analysis & Forecast to 2020  MyNewsDesk1 day ago Pain Management Drugs Market is likely to gain relatively higher over the several coming years  MyNewsDesk1 day ago
[x]  

Daiichi Sankyo Announces New Global Head of Development

By a News Reporter-Staff News Editor at Drug Week Daiichi Sankyo, Inc. announced the appointment of Marielle Cohard-Radice, MD as Executive Vice President, Global Head of Development, effective September 2, 2016 (see also Pharmaceutical Companies). ...
 Pharmacy Choice4 days ago Daiichi Sankyo appoints Marielle Cohard-Radice Global Head of Development  Center Watch2 weeks ago Daiichi Sankyo promotes Marielle Cohard-Radice to new global head of development  Pharma Letter2 weeks ago New Global Head of Development for Daiichi Sankyo  PharmExec.com2 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - daiichi sankyo
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less